This is in distinct contrast to the treatment landscape of HER2-positive breast cancers, showing that while HER2-positive cancers are a molecularly-defined subset of tumours, contradictory trial results point to distinct tumour biology between both tumour types. This evidence concerns the gene ERBB2 and neoplasm.